EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure

Terukazu Kato iD, Keita Fukao, Takafumi Ohara, Noriyuki Naya, Ryukou Tokuyama iD, Susumu Muto, Hiroshi Fukasawa, Akiko Itai, Ken-Ichi Matsumura

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Terukazu Kato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan. Hauptthemen laut MEDLINE: Atherosclerosis, Piperidines, PPAR delta, Pyrrolidines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator-activated receptor δ (PPARδ) is considered to be a pharmaceutical target to treat metabolic diseases including atherosclerosis, but there is no PPARδ agonist available for clinical use. We have previously reported the discovery of piperidinyl/piperazinyl benzothiazole derivatives as a new series of PPARδ agonists using docking-based virtual screening methods. In the present study, we found that introduction of a pyrrolidine group into the 4-position of their central piperidine rings enhances hPPARδ activity and subtype selectivity. This led to the discovery of 21 having strong PPARδ agonist activity (EC50 = 3.6 nM) with excellent ADME properties. Furthermore, 21 significantly suppressed atherosclerosis progression by 50-60% with reduction of the serum level of MCP-1 in LDLr-KO mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisPiperidinesPPAR deltaPyrrolidinesAnimalsMiceAnti-Inflammatory AgentsThiazoles

Substanzen

Anti-Inflammatory AgentsPiperidinesPPAR deltaThiazoles4-(1-pyrrolidinyl)piperidinePyrrolidines

Autor:innen und Institutionen

  • Shionogi Pharmaceutical Research Center, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.
  • Institute of Medicinal Molecular Design, Inc., Tokyo 113-0033, Japan.

ORCID-Profile: Terukazu Kato, Ryukou Tokuyama

Zitieren

APA

Kato, T., Fukao, K., Ohara, T., Naya, N., Tokuyama, R., Muto, S., Fukasawa, H., Itai, A., & Matsumura, K. I. (2023). Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00932

Vancouver

Kato T, Fukao K, Ohara T, Naya N, Tokuyama R, Muto S, et al. Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00932

BibTeX
@article{Kato2023,
  author = {Kato, Terukazu and Fukao, Keita and Ohara, Takafumi and Naya, Noriyuki and Tokuyama, Ryukou and Muto, Susumu and Fukasawa, Hiroshi and Itai, Akiko and Matsumura, Ken-Ichi},
  title = {Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00932}
}
Kostenlos starten →